论文部分内容阅读
急性髓性白血病（AML）在儿童中发病率逐年增加，据北京儿童医院统计近十年来急性淋巴细胞白血病（ALL）与AML比例由5：1上升至3：1。多年来各家认为DA、HA和TA方案是治疗AML有效的方案，其缓解率在30％左右，一次DA诱导达CR者16．67％，2次DA方案约32．22％病例达CR，自1994年以来应用DAE方案诱导治疗AML，使一次DAE方案CR可达51．02％，2次达73．43％，提高了AML在短时间内达CR的疗效，为进一步化疗奠定了基础。同时对DA和DAE方案骨髓抑制状况作了比较，两组无明显差异。此方案对于无层流设施的一般医院治疗AML提供一项容易推广的措施。
The incidence of acute myeloid leukemia (AML) is increasing year by year in children. According to statistics from Beijing Children’s Hospital, the proportion of acute lymphoblastic leukemia (ALL) and AML increased from 5:1 to 3:1 in the past decade. Over the years, various companies have considered DA, HA, and TA regimens to be effective regimens for AML treatment. The remission rate is about 30%. One DA induced 16.67% of CR patients, and two DA programs of about 32.22% of patients achieved CR. Since the application of DAE in the treatment of AML since 1994, the DA of the DAE protocol has reached 51.02% and 73.43% on two occasions, which has improved the efficacy of AML in achieving CR in a short period of time, which laid the foundation for further chemotherapy. At the same time, the myelosuppression status of DA and DAE programs was compared and there was no significant difference between the two groups. This program provides an easy-to-promote measure for general hospital treatment of AML without laminar flow facilities.